Compare Novartis with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs ALKEM LABORATORIES - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS ALKEM LABORATORIES NOVARTIS/
ALKEM LABORATORIES
 
P/E (TTM) x 1,959.2 22.8 8,598.4% View Chart
P/BV x 26.0 5.5 473.2% View Chart
Dividend Yield % 1.7 0.9 192.4%  

Financials

 NOVARTIS   ALKEM LABORATORIES
EQUITY SHARE DATA
    NOVARTIS
Mar-19
ALKEM LABORATORIES
Mar-20
NOVARTIS/
ALKEM LABORATORIES
5-Yr Chart
Click to enlarge
High Rs9802,720 36.0%   
Low Rs6001,660 36.1%   
Sales per share (Unadj.) Rs198.7697.9 28.5%  
Earnings per share (Unadj.) Rs21.096.1 21.8%  
Cash flow per share (Unadj.) Rs22.3117.3 19.0%  
Dividends per share (Unadj.) Rs10.0025.00 40.0%  
Dividend yield (eoy) %1.31.1 110.9%  
Book value per share (Unadj.) Rs307.5515.2 59.7%  
Shares outstanding (eoy) m24.69119.57 20.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.03.1 126.7%   
Avg P/E ratio x37.722.8 165.4%  
P/CF ratio (eoy) x35.518.7 190.1%  
Price / Book Value ratio x2.64.3 60.4%  
Dividend payout %47.726.0 183.4%   
Avg Mkt Cap Rs m19,508261,879 7.4%   
No. of employees `0000.614.3 4.1%   
Total wages/salary Rs m1,17115,055 7.8%   
Avg. sales/employee Rs Th8,445.45,822.6 145.0%   
Avg. wages/employee Rs Th2,015.71,050.5 191.9%   
Avg. net profit/employee Rs Th891.0802.0 111.1%   
INCOME DATA
Net Sales Rs m4,90783,444 5.9%  
Other income Rs m7831,042 75.1%   
Total revenues Rs m5,68984,486 6.7%   
Gross profit Rs m12314,734 0.8%  
Depreciation Rs m322,528 1.3%   
Interest Rs m16651 2.4%   
Profit before tax Rs m85812,598 6.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3401,105 30.8%   
Profit after tax Rs m51811,493 4.5%  
Gross profit margin %2.517.7 14.2%  
Effective tax rate %39.68.8 452.0%   
Net profit margin %10.613.8 76.6%  
BALANCE SHEET DATA
Current assets Rs m8,05554,960 14.7%   
Current liabilities Rs m1,85032,433 5.7%   
Net working cap to sales %126.427.0 468.4%  
Current ratio x4.41.7 256.9%  
Inventory Days Days4580 56.6%  
Debtors Days Days3472 47.0%  
Net fixed assets Rs m15032,710 0.5%   
Share capital Rs m123239 51.6%   
"Free" reserves Rs m7,46961,368 12.2%   
Net worth Rs m7,59261,607 12.3%   
Long term debt Rs m01,592 0.0%   
Total assets Rs m9,82499,433 9.9%  
Interest coverage x54.920.4 269.8%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.50.8 59.5%   
Return on assets %5.412.2 44.5%  
Return on equity %6.818.7 36.6%  
Return on capital %11.521.0 54.9%  
Exports to sales %019.1 0.0%   
Imports to sales %03.0 0.0%   
Exports (fob) Rs mNA15,917 0.0%   
Imports (cif) Rs mNA2,483 0.0%   
Fx inflow Rs m5816,061 0.4%   
Fx outflow Rs m1,3262,483 53.4%   
Net fx Rs m-1,26913,578 -9.3%   
CASH FLOW
From Operations Rs m-1,9435,851 -33.2%  
From Investments Rs m2,742-7,414 -37.0%  
From Financial Activity Rs m-298792 -37.7%  
Net Cashflow Rs m501-731 -68.6%  

Share Holding

Indian Promoters % 0.0 66.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 33.1 6.0%  
FIIs % 1.6 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 0.0 -  
Shareholders   41,647 68,381 60.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   STRIDES PHARMA SCIENCE  AJANTA PHARMA  ALEMBIC  ALEMBIC PHARMA  CADILA HEALTHCARE  

Compare NOVARTIS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 154 Points Lower, Nifty Ends at 14,834; Bajaj Finance and UPL Among Top Losers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended marginally lower.

Related Views on News

NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

A Critical Update on the Market(Fast Profits Daily)

Mar 30, 2021

In this video, I'll tell you why I am recommending caution in the market at this time.

My Recent Recommendation Will Profit from the Global Supply Chain Crisis(Profit Hunter)

Mar 31, 2021

A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.

My Stock Trading Strategy(Fast Profits Daily)

Mar 31, 2021

In this video I'll show you exactly how I go about picking stocks for trading.

What You Need to Find Hundred Baggers(Profit Hunter)

Mar 30, 2021

100 baggers of the last decade share this common trait. Here's how to use it to nail future multibaggers.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Apr 9, 2021 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - BIOCON COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS